To provide: an agent for the prevention and/or treatment of a depressive symptom, the drug consisting of (S)-norketamine or a pharmacologically acceptable salt thereof; a pharmaceutical composition for the prevention and/or treatment of a depressive symptom, the pharmaceutical composition containing (S)-norketamine or a pharmacologically acceptable salt thereof in an amount effective for alleviation of the depressive symptom, and being substantially free of (R)-norketamine; a method for the prevention and/or treatment of a depressive symptom, the method including administration of the drug or the composition; and use of (S)-norketamine for production of a drug for the prevention and/or treatment of a depressive symptom or a composition for the prevention and/or treatment of a depressive symptom.

The present invention relates to a coalescing agent as represented in structure (I); wherein; n is integer from 1 to 8; R.sup.1 and R.sup.2 independently represent group selected from hydrogen atom, alkyl, alkenyl, alkynyl, phenyl, benzyl groups, or optionally cyclic hydrocarbon containing heteroatom; and Y represents group selected from alkyl, alkenyl, alkynyl, phenyl, benzyl groups, or cyclic hydrocarbon containing heteroatom. The said coalescing agent can be used in coating application with efficacy to provide smooth consistent film with chemical and scratch resistant and has no pungent odour, wherein the preparation method of this compound is simplify and employs less harmful chemicals.

The present invention relates to a coalescing agent as represented in structure (I); wherein; n is integer from 1 to 8; R.sup.1 and R.sup.2 independently represent group selected from hydrogen atom, alkyl, alkenyl, alkynyl, phenyl, benzyl groups, or optionally cyclic hydrocarbon containing heteroatom; and Y represents group selected from alkyl, alkenyl, alkynyl, phenyl, benzyl groups, or cyclic hydrocarbon containing heteroatom. The said coalescing agent can be used in coating application with efficacy to provide smooth consistent film with chemical and scratch resistant and has no pungent odour, wherein the preparation method of this compound is simplify and employs less harmful chemicals.

The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.

The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.

The present invention relates to a solvent system characterized by the fact that is comprises one or more dioxolane-derived esters of formula I ##STR00001##
where R1, R2 and R3 are the same or different, selected from hydrogen, alkyl, alkenyl and phenyl, and n is an integer between 1 and 5.

The present invention relates to a solvent system characterized by the fact that is comprises one or more dioxolane-derived esters of formula I ##STR00001##
where R1, R2 and R3 are the same or different, selected from hydrogen, alkyl, alkenyl and phenyl, and n is an integer between 1 and 5.

A process produces a (meth)acrylate ester mixture. The process includes reacting a glycerol formal isomer mixture with an alkyl (meth)acrylate in the presence of a catalyst.

A process produces a (meth)acrylate ester mixture. The process includes reacting a glycerol formal isomer mixture with an alkyl (meth)acrylate in the presence of a catalyst.

The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.